Versor Investments LP Invests $612,000 in Integra LifeSciences Holdings Co. (NASDAQ:IART)

Versor Investments LP acquired a new stake in Integra LifeSciences Holdings Co. (NASDAQ:IART) in the 3rd quarter, according to the company in its most recent disclosure with the SEC. The fund acquired 33,700 shares of the life sciences company’s stock, valued at approximately $612,000.

A number of other large investors have also recently bought and sold shares of IART. Blue Trust Inc. lifted its position in shares of Integra LifeSciences by 100.5% in the second quarter. Blue Trust Inc. now owns 886 shares of the life sciences company’s stock worth $26,000 after buying an additional 444 shares during the last quarter. CWM LLC lifted its holdings in Integra LifeSciences by 50.8% in the 2nd quarter. CWM LLC now owns 1,262 shares of the life sciences company’s stock worth $37,000 after purchasing an additional 425 shares during the last quarter. Northwest Investment Counselors LLC bought a new stake in Integra LifeSciences during the third quarter worth approximately $73,000. Canada Pension Plan Investment Board acquired a new position in Integra LifeSciences during the second quarter valued at approximately $114,000. Finally, Allspring Global Investments Holdings LLC raised its position in shares of Integra LifeSciences by 58.0% in the second quarter. Allspring Global Investments Holdings LLC now owns 4,662 shares of the life sciences company’s stock valued at $136,000 after purchasing an additional 1,711 shares during the period. 84.78% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

Several research firms recently issued reports on IART. Citigroup upped their price objective on shares of Integra LifeSciences from $16.00 to $22.00 and gave the stock a “sell” rating in a report on Tuesday, November 5th. Truist Financial lowered their price target on Integra LifeSciences from $26.00 to $21.00 and set a “hold” rating on the stock in a research report on Monday, October 14th. BTIG Research raised Integra LifeSciences from a “sell” rating to a “neutral” rating in a research report on Monday, October 7th. Bank of America lowered their target price on Integra LifeSciences from $26.00 to $18.00 and set an “underperform” rating on the stock in a report on Monday, October 7th. Finally, JMP Securities cut their price target on Integra LifeSciences from $40.00 to $35.00 and set a “market outperform” rating for the company in a report on Tuesday, July 30th. Three research analysts have rated the stock with a sell rating, five have assigned a hold rating and two have given a buy rating to the company’s stock. According to data from MarketBeat, the stock presently has an average rating of “Hold” and a consensus target price of $27.25.

Integra LifeSciences Price Performance

Shares of IART stock opened at $23.31 on Thursday. The company has a market capitalization of $1.80 billion, a P/E ratio of -258.97, a P/E/G ratio of 0.84 and a beta of 1.08. The company has a current ratio of 1.20, a quick ratio of 0.73 and a debt-to-equity ratio of 0.79. Integra LifeSciences Holdings Co. has a 12 month low of $16.81 and a 12 month high of $45.42. The stock has a 50 day moving average of $19.37 and a two-hundred day moving average of $24.26.

Integra LifeSciences (NASDAQ:IART) last posted its quarterly earnings results on Monday, November 4th. The life sciences company reported $0.41 earnings per share for the quarter, topping analysts’ consensus estimates of $0.39 by $0.02. Integra LifeSciences had a negative net margin of 0.42% and a positive return on equity of 12.35%. The firm had revenue of $380.80 million for the quarter, compared to the consensus estimate of $375.81 million. During the same quarter in the previous year, the company earned $0.76 earnings per share. The business’s revenue was down .4% compared to the same quarter last year. As a group, equities analysts expect that Integra LifeSciences Holdings Co. will post 2.45 EPS for the current year.

Integra LifeSciences Company Profile

Integra LifeSciences Holdings Corporation manufactures and sells surgical instruments, neurosurgical products, and wound care products for use in neurosurgery, neurocritical care, and otolaryngology. It operates in two segments, Codman Specialty Surgical and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment; and surgical headlamps and instrumentation, as well as after-market services.